Recommended Treatment Plan for Managing Asthma
The cornerstone of asthma management is a stepwise approach using inhaled corticosteroids (ICS) as first-line controller medication, with the addition of long-acting beta-agonists (LABAs) for moderate to severe persistent asthma, alongside proper patient education and self-management plans. 1
Classification and Initial Assessment
Asthma severity should be classified to determine appropriate treatment:
- Mild Intermittent: Symptoms ≤2 times/week, nocturnal symptoms ≤2 times/month
- Mild Persistent: Symptoms >2 times/week but not daily
- Moderate Persistent: Daily symptoms, nocturnal symptoms >1 time/week
- Severe Persistent: Continuous symptoms, frequent nocturnal symptoms
Stepwise Treatment Approach
Step 1: Mild Intermittent Asthma
- Short-acting β2-agonist (SABA) as needed for symptom relief
- No daily controller medication needed 1
Step 2: Mild Persistent Asthma
- Low-dose inhaled corticosteroid (preferred controller)
- Alternative: leukotriene modifier, cromoglycate, or nedocromil 1
Step 3: Moderate Persistent Asthma
- Low-dose inhaled corticosteroid plus long-acting β2-agonist (preferred)
- Alternative: Medium-dose inhaled corticosteroid
Step 4: Severe Persistent Asthma
- High-dose inhaled corticosteroid plus long-acting β2-agonist
- Consider adding oral corticosteroids for severe uncontrolled asthma 1
Key Components of Management
Environmental Trigger Control:
- Identify and minimize exposure to allergens and irritants
- Address occupational exposures if relevant
Patient Education (essential component):
- Proper inhaler technique
- Difference between "relievers" (bronchodilators) and "preventers" (anti-inflammatory)
- Recognition of worsening symptoms, especially nocturnal symptoms
- Written action plan 1
Objective Monitoring:
- Peak flow monitoring
- Symptom tracking
- Regular assessment of control
Self-Management Plan should include:
- Monitoring symptoms, peak flow, and medication use
- Taking pre-arranged action based on symptoms/peak flow
- Written guidance for medication adjustments 1
Medication Considerations
Inhaled Corticosteroids: The mainstay of preventive treatment
- Use lowest effective dose for acceptable symptom control
- Standard daily dose of 200-250 μg fluticasone propionate (or equivalent) achieves 80-90% of maximum therapeutic benefit 4
Combination Therapy: Adding LABA to ICS provides greater asthma control than doubling ICS dose 3
Acute Exacerbation Management
For acute severe asthma:
Immediate Treatment:
- High-flow oxygen
- Nebulized β-agonist (salbutamol 5 mg or terbutaline 10 mg)
- Systemic corticosteroids (prednisolone 30-60 mg or IV hydrocortisone 200 mg) 1
Hospital Admission Criteria:
- Life-threatening features
- Features of severe asthma persisting after initial treatment
- PEF <33% of predicted/best after treatment 1
Follow-up and Monitoring
- Regular reassessment of symptom control
- Step down therapy once control is maintained for 3 months
- Reducing ICS dose within combination therapy is preferable to removing LABA 6
- Monitor for adverse effects of medications
- Check inhaler technique at each visit
Common Pitfalls to Avoid
- Undertreatment: Failing to prescribe controller medications for persistent asthma
- Overreliance on SABAs: Using rescue medication frequently without adding controller medication
- Poor inhaler technique: Leads to suboptimal medication delivery
- Lack of written action plan: Patients need clear guidance on how to respond to worsening symptoms
- Failure to address adherence: Regular assessment of medication use is essential
- Inadequate follow-up: Regular monitoring is needed to adjust therapy as needed
Remember that successful asthma management should result in minimal symptoms during the day, no nighttime waking, full participation in activities, and infrequent need for rescue medication 1.